| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pathophysiology of Renal Disease and Progression |



* Division of Nephrology, University Hospital RWTH Aachen, Aachen, Germany;
Department of Clinical and Experimental Pharmacotherapy, Slovak Medical University, Bratislava, Slovakia;
Institute of Biochemistry, University Hospital Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany; and
Department of Pathology, University of Vienna, Vienna, Austria
Address correspondence to: Dr. Uta Kunter, Division of Nephrology, University Hospital RWTH Aachen, Pauwelsstrasse 30, D-52057 Aachen, Germany. Phone: +49-241-8089670; Fax: +49-241-8082446; E-mail: utakunter{at}gmx.de
Received for publication January 12, 2007. Accepted for publication March 14, 2007.
| Abstract |
|---|
|
|
|---|
-smooth muscle actin. Approximately 20% of the glomeruli of MSC-treated rats contained single or clusters of large adipocytes with pronounced surrounding fibrosis. Adipocytes exhibited fluorescence in their cytoplasm and/or intracellular lipid droplets. Lipid composition in these adipocytes in vivo mirrored that of MSC that underwent adipogenic differentiation in vitro. Thus, in this GN model, the early beneficial effect of MSC of preserving damaged glomeruli and maintaining renal function was offset by a long-term partial maldifferentiation of intraglomerular MSC into adipocytes accompanied by glomerular sclerosis. These data suggest that MSC treatment can be a valuable therapeutic approach only if adipogenic maldifferentiation is prevented. | Introduction |
|---|
|
|
|---|
1 rather than by differentiation into resident glomerular cell types or monocytes/macrophages (6). In this study, we investigated the long-term effects of MSC administration in early anti-Thy1.1 nephritis. Normally, anti-Thy1.1 nephritis in rats follows a self-limited course, and spontaneous restitution of the glomerular architecture can be observed within approximately 4 wk. For enhancement of the relevance of the model for progressive renal disease in humans, the model in this study was aggravated and transformed into a course of progressive renal failure by previous uninephrectomy of the rats (7,8).
| Materials and Methods |
|---|
|
|
|---|
Harvest and Culture of MSC
Inbred male Lewis rats that weighed 180 to 210 g (Harlan, Horst, Netherlands) served as bone marrow donors; MSC were prepared as described previously (6). Cells were seeded onto six-well plates (nine wells per donor) and cultured at 37°C in a humidified atmosphere that contained 5% CO2. Medium was changed after 2 d and every 3 d thereafter. Nonadherent hematopoietic cells were removed when medium was changed. After a mean of 6 d, cells reached subconfluence and were detached with trypsin/EDTA, reseeded at 4 x 103 cells/cm2, and used for experiments after the third passage.
MSC features were demonstrated by typical spindle-shaped morphology as well as osteogenic and adipogenic differentiation under appropriate in vitro conditions. In addition, MSC were cultured in four-well chamber slides (LAB-TEK; Nalge Nunc Int., Naperville, IL). Upon confluence in passage 3, they were washed twice with PBS, fixed in acetone for 10 min, air-dried for 30 min, and stored at 80°C until use. These slides were tested for MSC-typical presence or absence of CD antigens (CD31, CD34, CD44, CD45, CD73, and CD90).
Fluorescence Labeling for In Vivo Tracking of Cells
Before in vivo injection, cells were labeled using the PKH26 red fluorescence cell linker kit (Sigma-Aldrich, St. Louis, MO) according to the manufacturer's protocol (6). Cells were resuspended at 1 x 106 cells/250 µl complete medium and used within 30 min.
PKH 26 labeling did not affect MSC viability, because reseeding of such cells yielded >95% viable cells, which could be induced to differentiate like the unlabeled cells (data not shown). After in vivo experiments, PKH26-specific fluorescence was detected in frozen kidney samples as described previously (6).
Osteogenic and Adipogenic Differentiation of MSC
Osteogenic differentiation of Lewis MSC was tested following the protocol of Bruder et al. (US patent 5,736,396), as described previously (6). Adipogenic differentiation of MSC was tested following the protocol of M. Pittenger (US patent 5,827,740). Subconfluent MSC after the second passage were incubated in adipogenic differentiation medium (Cambrex, Charles City, IA). After 15 d, both Oil red O and Nile blue staining was performed. In addition, 1 d before and 16 d after start of adipogenic differentiation, MSC were harvested and total mRNA was extracted. Cultured rat mesangial cells that were grown in basal medium (RPMI 1640 with 10% FCS, l-glutamine, and 1% penicillin/streptomycin; all Cambrex) served as negative controls for fat cell differentiation.
Real-Time Quantitative Reverse TranscriptasePCR
Total RNA was isolated from MSC, and real-time reverse transcriptasePCR was performed as described previously (9). The primer sequences are listed in Table 1. Glyceraldehyde-3-phosphate dehydrogenase was used as an internal standard.
|
Renal Morphology
Tissue for light microscopy was fixed in methyl Carnoy solution and embedded in paraffin. Four-micron sections were stained with periodic acid-Schiff (PAS) and counterstained with hematoxylin. For the evaluation of total collagen, renal tissues were stained with Sirius red. Fat cells were demonstrated in frozen kidney sections using Oil red O staining for the identification of all types of lipids and Nile blue staining for identification of neutral versus acidic lipids.
Immunoperoxidase Staining
Four-micrometer sections of methyl Carnoyfixed biopsy tissue or acetone-fixed cellular monolayers that were grown on coverslips were processed by an indirect immunoperoxidase technique as described previously (10). Primary antibodies were identical to those described previously (11,12) and included murine mAb to
-smooth muscle actin (
-SMA; clone 1A4; DAKO, Carpinteria, CA) to a cytoplasmic antigen present in monocytes, macrophages, and dendritic cells (clone ED-1; Serotec, Oxford, UK) and to human muscle desmin that cross-reacts with rat desmin (clone D33; DAKO), plus goat polyclonal antibodies to human collagen types I, III, and IV (Southern Biotech, Birmingham, AL) that cross-react with rat collagen type I, III, and IV, plus appropriate negative controls using irrelevant antibodies. Primary antibodies for the characterization of cultured MSC included mouse mAb against rat CD31 (clone TLD-3A12; Serotec), rat CD34 (ICO115; Santa Cruz Biotechnology, Santa Cruz, CA), CD44 (MCA643GA; Serotec), rat CD73 (BD Pharmingen, Heidelberg, Germany), rat CD90 (clone OX7; Mediagnost, Reutlingen, Germany), and a goat polyclonal antibody against rat CD45 (M-20; Santa Cruz) plus appropriate negative controls using irrelevant antibodies.
Evaluation of Histologic Sections
All slides were evaluated by an observer who was unaware of their origin. In PAS-stained sections, the number of total mitotic figures within 100 to 150 glomerular cross-sections was determined as described previously (10). Mesangiolysis was graded on a semiquantitative scale (0, no mesangiolysis; 1, segmental mesangiolysis; 2, global mesangiolysis; 3, microaneurysm) as described previously (10). In addition, we counted the number of glomeruli that showed adhesions to Bowman's capsule. On day 60, the percentage of glomeruli that exhibited focal or global glomerulosclerosis was determined as described previously (13). Tubulointerstitial injury, defined as inflammatory cell infiltrates, tubular dilation, and/or atrophy or interstitial fibrosis on day 60, was graded on a scale of 0 to 4 as described previously (14). The total number of glomerular cross-sections was determined by counting within a longitudinal renal 4-µm section all glomeruli per 20 consecutive 1-mm2 areas of the renal cortex. In sections that stained for the ED-1 antigen, total numbers of positive cells per 100 glomeruli were counted. Immunostaining for glomerular
-SMA; desmin; as well as types I, III, and IV collagen was evaluated using a point-counting method as described previously (8). Tubulointerstitial staining (Sirius red; collagen types I, III, IV; and ED-1) was evaluated by computer histomorphometry as described previously (8).
Electron Microscopy
Tissue for electron microscopy was fixed in half-strength Karnovsky solution (1% paraformaldehyde and 1.25% glutaraldehyde in 0.1 M sodium cacodylate buffer [pH 7.0]). After fixation, tissue was postfixed in 1% osmium tetroxide for 2 h, dehydrated in graded ethanols, and embedded in epoxy resin. Thin sections were stained with uranyl acetate and lead citrate and examined with a Phillips 410 (Phillips Export BV, Eindhoven, Netherlands) electron microscope. Kidney tissue examined included at least two and usually three or more glomeruli per rat as well as cortical and medullary interstitium, tubules, and blood vessels.
Miscellaneous Measurements
BP were measured by tail-cuff plethysmography on days 10, 30, and 60 in conscious rats using a programmed sphygmomanometer (BP-981; Softron, Tokyo, Japan). On days 10, 30, and 60, serum creatinine, SUN, and urinary protein excretion were measured by an autoanalyzer (Vitros 250 analyzer; Orthoclinical Diagnostics, Neckargmünd, Germany). Ratios of urinary proteinuria/urinary creatinine and creatinine clearances were calculated from 24-h urine collections.
Statistical Analyses
All values are presented as means ± SD. Statistical significance was evaluated using one-way ANOVA with modified t test performed with the Bonferroni correction. Repeated measurements of serum creatinine, SUN, and proteinuria were also tested using two-way repeated measures ANOVA.
| Results |
|---|
|
|
|---|
|
|
In PAS-stained renal biopsies of day 10, ARF was evidenced by widened and flattened tubular cells and intratubular cast formation (data not shown). MSC injection significantly reduced serum creatinine and SUN, confirmed by a higher creatinine clearance, on day 10 when compared with medium controls but did not affect the mild proteinuria or BP (Table 2).
|
-SMA were not affected by MSC treatment, but the de novo expression of collagen type I increased significantly in the MSC group (Table 2).
MSC Reduce Proteinuria and Improve Renal Function at Follow-Up
All rats recovered from ARF by day 30, and serum creatinine and creatinine clearance values almost normalized in both groups. However, SUN remained significantly lower in MSC- versus medium-treated rats (Table 2). On day 60, serum creatinine started to rise again in both groups, and the difference failed to reach statistical significance (P = 0.09). Nevertheless, both groups showed further recovery of creatinine clearance. SUN on day 60 remained significantly lower in MSC-treated rats (Table 2). In parallel, proteinuria remained low in the MSC group on day 60, whereas it doubled in the control group between days 30 and 60 (Table 2). Measurement of urine proteinuria/creatinine ratios confirmed these findings. BP remained normal at all time points, and mean body weight at the end of follow up was comparable in both groups (Table 2).
MSC Treatment Reduces Loss of Glomeruli during Mesangiolytic Injury and Tubulointerstitial Fibrosis
On day 60, PAS-stained sections in all rats revealed glomeruli in various stages of repair or sclerosis besides very few glomeruli with relatively normal morphology (Figure 3, A and B). Approximately 20% of the glomeruli in MSC-treated rats exhibited large, "empty" defects of varying size. Adhesions between the glomerular tuft and Bowman's capsule occurred at similar frequencies (approximately 60%) in the two groups (data not shown). MSC treatment led to better preservation of glomeruli after the initial mesangiolytic injury, as evidenced by significantly more glomeruli per 1-mm2 section of renal cortex (Figure 3C).
|
MSC Treatment Leads to Persistent Mesangial Cell Activation on Day 60
Glomerular markers of mesangial cell activation (the de novo expression of
-SMA and interstitial collagen types [types I and III]) decreased by >50% between day 10 (Table 2) and day 60 (Figure 4, A through G). However, in MSC-treated rats on day 60, glomerular de novo expression of
-SMA (Figure 4, A through C), as well as the de novo expression of collagen type I (Figure 4, D through F) and type III (Figure 4G) and the constitutive expression of collagen type IV (Figure 4H) all were significantly increased as compared with the control group. In contrast, the expression of glomerular desmin, which is constitutively expressed by mesangial cells and de novo by activated podocytes, was not different between the groups (data not shown). Glomerular monocyte/macrophage counts were also not affected by MSC treatment on day 60 (data not shown).
|
-SMA (Figure 5, C through F) as well as some monocytes/macrophages (Figure 5B). Within or adjacent to these areas, we frequently noted small cells with intense cellular staining for collagen types I and III (Figure 5, D and E, arrows) and Sirius red positivity (Figure 5H), which in serial sections failed to co-localize to ED-1positive areas. Desmin expression in vacuolic areas was similar or less intense when compared with the rest of the glomerulus (Figure 5G). When examined by electron microscopy, the vacuoles were exclusively located intracellularly (Figure 5, I through K). Cells that contained individual large vacuoles as well as numerous small droplets strongly resembled the ultrastructural morphology of adipocytes. Even univacuolated cells, strongly resembling mature, signet-ring white adipocytes, were noted (Figure 5I). Oil red O staining confirmed that the cells contained lipids (triglycerides; Figure 5L), and Nile blue staining demonstrated the presence of neutral lipids (Figure 5M). In most cases, PKH26 fluorescence surrounded the nonfluorescent vacuolar areas (Figure 2C). In other cases, fluorescence was noted within fat vacuoles (Figure 2D).
|
|
Finally, we tried to assess whether adipogenic maldifferentiation may have started early during nephritis. On day 10 after disease induction (i.e., 8 d after MSC injection), Oil red O stainings (Figure 6C) and electron microscopy analyses (Figure 6, A and B) failed to detect intraglomerular fat cells. In vitro expression of typical fat cell markers (adiponectin, leptin, lipoprotein lipase, and peroxisome proliferatoractivated receptor-
) was low in undifferentiated MSC (passage 3), although higher than in mesangial cell controls. After 16 d of exposure to adipogenic induction medium and visible formation of fat cell clusters, the increase in expression of these markers was five-fold (leptin), 107-fold (peroxisome proliferatoractivated receptor-
), 248-fold (lipoprotein lipase), and 2572-fold (adiponectin; Figure 6D). We therefore conclude that the molecular profile of our cells before adipogenic differentiation differs substantially from that of differentiated adipocytes.
| Discussion |
|---|
|
|
|---|
The first major finding was that MSC in our aggravated model of anti-Thy1.1 nephritis potently ameliorated early ARF, which confirms our own and others' recent data in a less severe variant of this model (6,16). This effect likely resulted from paracrine effects of the transplanted MSC (6), leading to the reduction in glomerular adhesion formation and better long-term preservation of glomeruli observed in this study. As has been described before (4,5,6,17), MSC secrete high concentrations of growth factors such as VEGF, TGF-
, and hepatocyte growth factor. In particular, proangiogenic effects of VEGF (16) might help to restitute glomerular capillaries better. In contrast, we (6) and others (5) failed to detect any evidence of transdifferentiation of MSC into glomerular, tubular, or renal interstitial cells. Therefore, the reduction of tubulointerstitial fibrosis that was observed in our MSC-treated rats likely was a secondary effect, related to the better preservation of glomeruli. Functionally, our early MSC treatment led to a marginally better renal function on day 60 and prevented the progressive increase in proteinuria, consistent with better preservation of glomeruli.
The second major finding of our study was that on day 60, approximately 20% of the MSC-treated glomeruli contained cells that exhibited typical features of adipocytes. It seems highly likely that these originated from the transplanted MSC for several reasons: (1) Similar cells were never observed in the control group; (2) in a multitude of spontaneous or induced models of glomerular disease as well as in human glomerular disease, we never observed glomerular adipocytes; (3) lipid characterization yielded similar findings in the adipocytes in vivo and in MSC that underwent adipogenic differentiation in vitro; and (4) the adipocytes were almost always surrounded by intense PKH26-specific fluorescence or the lipid even contained it. Nevertheless, this does not allow us to count distinct MSC offspring. Some areas exhibited diffuse and weak PKH26 fluorescence, and several phenomena may underlie the staining pattern, including (1) MSC division and thereby dilution of the dye, (2) cell death and uptake of the dye by neighboring cells, and (3) diffusion of the dye into the lipid droplets.
Are the adipocytes indeed derived from MSC or from other bone marrow cells that contaminated the preparation? Despite culture under particular conditions before transplantation of the MSC, the latter cannot be formally excluded, because no specific MSC markers are available. However, on the basis of recommendations of a consensus paper on MSC characterization (15), our cells fully matched the consensus requirements. To rule out a contamination of the injected cells by adipocytes, we first showed that nephritic, MSC-injected kidneys on day 10 showed no signs of adipocyte formation or accidental adipocyte transplantation. Furthermore, before and after induction of adipogenic MSC differentiation, we noted an up to 2500-fold increase of adipocyte markers. This renders it very unlikely that our cell cultures might have been contaminated by significant numbers of mature adipocytes or even preadipocytes. Another possible explanation is adipocyte formation as a result of intrinsic glomerular cells' reacting to neighboring MSC. This cannot be formally excluded because of the given technical limitations of long-term cell tracking, but we want to stress that no other condition in which glomerular cells differentiate to adipocytes in vivo or in vitro is known.
Glomerular adipocyte formation in MSC-treated rats was accompanied by a pronounced fibrotic response, which may largely account for the highly significant increase in glomerular deposition of collagen types I, III, and IV and the smooth muscle cell marker
-SMA on day 60 (Figure 4). Whether this fibrotic wall, in particular the small cells that were very intensely positive for collagens type I and III and directly adjacent to the adipocytes, derived from activated mesangial cells or MSC is unknown, because both can express collagen types I and III (18,19). MSC-derived adipocytes may contribute to a fibrotic response via mechanic stretch or through their proinflammatory activity (20,21). Our data resemble findings that were obtained in the lung, where murine MSC were trapped, and formed cysts with adjacent collagen depositions, resulting in severe lung damage (22).
Despite the apparent maldifferentiation of glomerular MSC into adipocytes and the fibrotic response surrounding them, which might have decreased GFR, renal function on day 60 after disease induction, if at all, was better preserved than that of controls. This is likely the consequence of two counteracting effects of MSC treatment: Improved early preservation of glomeruli during mesangiolysis on the one hand and maldifferentiation and fibrosis in approximately 20% of glomeruli on the other hand. Whether a similar mutual neutralization of beneficial and adverse effects would also occur in other models remains to be determined. However, the morphologic aspect of glomeruli that contain adipocytes strongly suggests that these glomeruli should exhibit a marked functional impairment and ultimately develop global glomerulosclerosis.
MSC have the ability to differentiate into new phenotypes along particular mesenchymal lineages in response to various microenvironments (23). Mesenchymal differentiation includes adipocytes, osteocytes, and chondrocytes, but MSC plasticity can also lead to "unorthodox" differentiation toward hepatocytes, (24), cardiomyocytes (25), and neural cells (26). Whether "orthodox" or "unorthodox" differentiation, it is always expected to take place in the appropriate environment and to the benefit of the individual. Here we show for the first time "orthodox" differentiation of MSC into fat cells but in an inappropriate, "unorthodox" location.
Why did our MSC differentiate into adipocytes but not osteocytes or chondrocytes? At least in the case of chondrogenic differentiation, stem cells in vivo have to be pelleted to form a micromass and have to be cultured as such. A glomerulus therefore may not provide adequate physical conditions for chondrogenic differentiation. Rather, TGF-
, which is secreted in high amounts by our MSC in vitro (6), acts as a major signal for adipogenesis (27,28). Another factor that strongly enhances adipogenic differentiation of MSC in vitro is basic fibroblast growth factor (29), which is released within the glomerulus during early anti-Thy1.1 nephritis (30). Finally, human adipocytes express Fc receptors, and lipogenesis is stimulated by Ig as efficiently as by insulin (20). Elevated Ig levels during anti-Thy1.1 nephritis therefore could contribute to adipogenesis.
Others have experienced unwanted, stem cellassociated phenomena as well. Wu et al. (31) showed fibroblast-like differentiation of MSC in the setting of chronic heart allograft rejection. Toegel et al. (32) reported the formation of unique "proximal tubular pseudocrescents" in the glomeruli of mice after mobilization of hematopoietic stem cells with cyclophosphamide and G-CSF before induction of acute ischemic renal failure. However, in that study, it remained unclear whether stem cells contributed to this phenomenon, because pseudocrescents were very rarely noted in control groups as well. Finally, stem cells can contribute to malignancy, for example, via teratoma formation after injection of embryonic stem cells (33), in Helicobacter-associated gastric cancer (34), or by tumor-associated myofibroblasts and fibroblasts (35).
Others (36,37) have studied the contribution of either normal or intravenously infused bone marrow to the regeneration of damaged glomeruli in a rat model similar to ours. It was found that bone marrow mainly contributed to glomerular endothelial cell regeneration, and infused bone marrow prevented death of nephritic animals in the study of Li et al. (37). In both studies, no intraglomerular adipocytes were noted after 11 to 12 wk, again suggesting that intraglomerular adipogenesis in our study does not happen during the normal course of the disease model but must be linked directly to intraglomerular injection of MSC. Given this, our findings are in line with the new ecological concept of the stem cell niche (38).
Our novel observation of "orthodox MSC differentiation" in an "unorthodox location" raises considerable concerns about the safety of MSC-based cell therapies. Resolving these concerns will require extensive tests to evaluate how to prevent such unwanted differentiation. For example, in the case of MSC, preincubation with PDGF-B or retinoid acid induced a mesangial celllike phenotype in vitro (39). Alternatively, other sources for MSC might be used: Kern et al. (40) showed that MSC from bone marrow or adipose tissue but not those from umbilical cord blood can differentiate into adipocytes. Prolonged ex vivo expansion of human MSC and senescence itself led to a loss of adipogenic differentiation potential and therefore might render MSC less susceptible to maldifferentiation in vivo (41).
| Disclosures |
|---|
|
|
|---|
| Acknowledgments |
|---|
The help of Gabi Dietzel, Andrea Cosler, Gerti Minnartz, and Katrin Haerthel is gratefully acknowledged.
| Footnotes |
|---|
Published online ahead of print. Publication date available at www.jasn.org.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
F. Togel, Y. Yang, P. Zhang, Z. Hu, and C. Westenfelder Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury Am J Physiol Renal Physiol, July 1, 2008; 295(1): F315 - F321. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Razzaque Can patient-specific stem cell therapy enhance renal repair? Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1826 - 1830. [Full Text] [PDF] |
||||
![]() |
B. Mazzinghi, E. Ronconi, E. Lazzeri, C. Sagrinati, L. Ballerini, M. L. Angelotti, E. Parente, R. Mancina, G. S. Netti, F. Becherucci, et al. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homingof human renal progenitor cells J. Exp. Med., February 18, 2008; 205(2): 479 - 490. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |